HanX Biopharmaceuticals Announces HX009 IND Approval From FDA
Recommended
HanX Biopharmaceuticals Announces HX009 IND Approval From FDA
The FDA has granted investigational new drug approval to HanX Biopharmaceuticals for the first-in-class recombinant anti-CD47/PD-1 bispecific antibody HX009 to be trialed in patients with relapsed/refractory lymphoma who have failed standard therapy.
Access the full article to read more here.
<!-- BEGIN ADVERTSERVE CODE -->
<div id="mobile_block_ad_1"><script type="text/javascript">
var _avp = _avp || [];
_avp.push({ tagid: 'mobile_block_ad_1', alias: '/', type: 'banner', zid: 1669, pid: 0, onscroll: 0, inview: true, secure: true });
</script></div>
<!-- END ADVERTSERVE CODE -->